Chinese biopharmaceutical company Mabwell (SH:688062) announced on Tuesday the first patient dosing in the United States for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) in triple-negative breast cancer (TNBC) patients previously treated with antibody-drug conjugate (ADC).

This is the first overseas clinical study of 9MW2821. Mabwell said that it represents a significant step in its global development of ADC therapeutics.

The multicentre clinical study aims to evaluate the efficacy and safety of BFv in TNBC patients previously treated with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload. The first subject has been dosed at Memorial Sloan Kettering Cancer Center.

BFv is a novel Nectin-4 targeting ADC leveraging next-generation site-specific conjugation technology. BFv is protected by multiple patents in China and internationally through the PCT.